kw-2450
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00921336)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
IGF1R inhibitor
- Insulin receptorINHIBITOR
INSR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(S(=O)(=O)O)cc1.Cc1ccsc1C(=O)Nc1cc(CN2CCN(C(=O)CO)CC2)ccc1/C=C/c1n[nH]c2ccccc12- Mol. weight
- 687.84 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5283463 ↗
- ChEMBLCHEMBL3545156 ↗
Also known as
- kw-2450
- kw-2450
- kw-2450
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01199367 | Phase 1 | Dec 1, 2010 | Kyowa Hakko Kirin |
| NCT00921336 | Phase 1 | Jun 1, 2009 | Kyowa Hakko Kirin |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 2 | 2 | 1 | 2009 |
1 organizations
Page 1 / 1